Trials / Conditions / Affective Disorders, Psychotic

Affective Disorders, Psychotic

14 registered clinical trials studyying Affective Disorders, Psychotic — 1 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	CBT-CP for Veterans With SMI NCT06758414	VA Office of Research and Development	N/A
Completed	Arts-based Social Prescribing for Mental Health NCT07137572	KAVADIA ELENI	N/A
Completed	Assessment and Treatment for Chronic Pain in Veterans With Serious Mental Illness NCT04118283	VA Office of Research and Development	N/A
Completed	Early Psychosis Intervention - Spreading Evidence-based Treatment NCT03919760	Centre for Addiction and Mental Health	N/A
Completed	Anomalous Self-Experience in First Episode Psychosis - A Six-Year Follow-Up Study NCT02321943	Sykehuset Innlandet HF	—
Completed	Self-Management and Recovery Technology Psychosocial Intervention Trial NCT02474524	Swinburne University of Technology	N/A
Completed	Implementation of Illness Management and Recovery in Mental Health Services NCT02077829	University Hospital, Akershus	N/A
Completed	Web-Based Weight Management for Individuals With Mental Illness NCT01324973	University of California, Los Angeles	N/A
Completed	Clinical Validation of the Rating Scale for Psychotic Depression (RAS-PD) NCT01518049	Søren Dinesen Østergaard	—
Completed	Smoking Cessation for Veterans With Severe and Persistent Mental Illness NCT00960375	US Department of Veterans Affairs	Phase 2 / Phase 3
Terminated	Treatment of Psychotic Major Depression With Mifepristone NCT00867360	Stanford University	Phase 3
Completed	Routine Plasma Level Determination to Compare Actual vs Expected Plasma Levels at Psychiatric Inpatient Admiss NCT00627510	Medical University Innsbruck	—
Completed	A Study to Evaluate the Safety and Effectiveness of Topiramate Compared to Placebo in the Treatment of Patient NCT00035802	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	Phase 3
Completed	A Study of the Effectiveness and Safety of Topiramate in the Treatment of Patients With Bipolar Disorder NCT00240721	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	Phase 3